





In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” “the Company”, “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.

Item 2.02 - Results of Operations and Financial Condition

On March 6, 2017, the Company issued a press release reporting our financial results for the fourth quarter and full year ended December 31, 2016. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
99.1	Press release issued March 6, 2017, reporting financial results for the fourth quarter and full year ended December 31, 2016



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

INNOVUS PHARMACEUTICALS, INC.

/s/ Robert E. Hoffman

Date: March 6, 2017 By: Robert E. Hoffman

Executive Vice President, Chief Financial Officer



EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release issued March 6, 2017, reporting financial results for the fourth quarter and full year ended December 31, 2016